Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Manancial - Repositório Digital da UFSM |
Texto Completo: | http://repositorio.ufsm.br/handle/1/9007 |
Resumo: | The yeast Malassezia pachydermatis belongs to the normal microbiota of animals, and is usually implicated as responsible for otitis media and recently by various forms of dermatitis, mainly in dogs. This study aimed to evaluate the in vitro susceptibility of 26 M. pachydermatis isolates against the antifungals fluconazole, itraconazole, ketoconazole, clotrimazole, miconazole, terbinafine and nystatin, and to the combinations of these with thymol, carvacrol and cinnamaldehyde by the checkerboard method, based on document M27-A3. The activity of itraconazol, ketoconazole and clotrimazole against 20 isolates of M. pachydermatis, through simultaneous and sequential exposure of these agents, was also evaluated by the disk-diffusion technique. The minimum inhibitory concentration (MIC) for fluconazole ranged from 1-64 μg/mL, itraconazole 0.01-1 μg/mL, ketoconazole 0.01-0.5 μg/mL, clotrimazole 0.5-32 μg/mL, miconazole 2-32 μg/mL, terbinafine 0.12-32 μg/mL and nystatin 16-64 μg/mL. High rates of synergism were observed in the combinations of nystatin + thymol (88.46%), nystatin + carvacrol (88.46%), nystatin + cinnamaldehyde (73.07%), clotrimazole + thymol (69.23%), clotrimazole + carvacrol (69.23%), miconazole + thymol (65.38%), miconazole + carvacrol (76.92%) and miconazole + cinnamaldehyde (65.38%). However, high rates of indifference were observed in the combinations of fluconazole + thymol (53.84%), carvacrol + fluconazole (46.15%), fluconazole + cinnamaldehyde (65.38%), thymol + itraconazole (61.53%), carvacrol + itraconazole (69.23%), itraconazole + cinnamaldehyde (65.38%), terbinafine + thymol (73.07%), terbinafine + carvacrol (65.38%), terbinafine + cinnamaldehyde (73.07%) and clotrimazole + cinnamaldehyde (61.53%). Ketoconazole combined with thymol, carvacrol and cinnamaldehyde had the highest rates of antagonism (42.3%). The prior exposure of M. pachydermatis to itraconazole resulted in a reduction of the inhibition halo when compared with itraconazole and ketoconazole used simultaneously (p <0.01). Moreover, prior exposure of clotrimazole significantly increased the zone of inhibition (p <0.001) when compared to the simultaneous exposure of itraconazole and clotrimazole. The most significant associations deserve in vivo evaluation in order to verify their potential in the treatment of infections caused by M. pachydermatis. |
id |
UFSM-20_856b1467569766a772df779092d4eb9d |
---|---|
oai_identifier_str |
oai:repositorio.ufsm.br:1/9007 |
network_acronym_str |
UFSM-20 |
network_name_str |
Manancial - Repositório Digital da UFSM |
repository_id_str |
3913 |
spelling |
2015-03-122015-03-122014-03-14SCHLEMMER, Karine Bizzi. IN VITRO SUSCEPTIBILITY OF Malassezia pachydermatis AGAINST ANTIFUNGAL AGENTS AND ESSENTIAL OIL FRACTIONS. 2014. 139 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014.http://repositorio.ufsm.br/handle/1/9007The yeast Malassezia pachydermatis belongs to the normal microbiota of animals, and is usually implicated as responsible for otitis media and recently by various forms of dermatitis, mainly in dogs. This study aimed to evaluate the in vitro susceptibility of 26 M. pachydermatis isolates against the antifungals fluconazole, itraconazole, ketoconazole, clotrimazole, miconazole, terbinafine and nystatin, and to the combinations of these with thymol, carvacrol and cinnamaldehyde by the checkerboard method, based on document M27-A3. The activity of itraconazol, ketoconazole and clotrimazole against 20 isolates of M. pachydermatis, through simultaneous and sequential exposure of these agents, was also evaluated by the disk-diffusion technique. The minimum inhibitory concentration (MIC) for fluconazole ranged from 1-64 μg/mL, itraconazole 0.01-1 μg/mL, ketoconazole 0.01-0.5 μg/mL, clotrimazole 0.5-32 μg/mL, miconazole 2-32 μg/mL, terbinafine 0.12-32 μg/mL and nystatin 16-64 μg/mL. High rates of synergism were observed in the combinations of nystatin + thymol (88.46%), nystatin + carvacrol (88.46%), nystatin + cinnamaldehyde (73.07%), clotrimazole + thymol (69.23%), clotrimazole + carvacrol (69.23%), miconazole + thymol (65.38%), miconazole + carvacrol (76.92%) and miconazole + cinnamaldehyde (65.38%). However, high rates of indifference were observed in the combinations of fluconazole + thymol (53.84%), carvacrol + fluconazole (46.15%), fluconazole + cinnamaldehyde (65.38%), thymol + itraconazole (61.53%), carvacrol + itraconazole (69.23%), itraconazole + cinnamaldehyde (65.38%), terbinafine + thymol (73.07%), terbinafine + carvacrol (65.38%), terbinafine + cinnamaldehyde (73.07%) and clotrimazole + cinnamaldehyde (61.53%). Ketoconazole combined with thymol, carvacrol and cinnamaldehyde had the highest rates of antagonism (42.3%). The prior exposure of M. pachydermatis to itraconazole resulted in a reduction of the inhibition halo when compared with itraconazole and ketoconazole used simultaneously (p <0.01). Moreover, prior exposure of clotrimazole significantly increased the zone of inhibition (p <0.001) when compared to the simultaneous exposure of itraconazole and clotrimazole. The most significant associations deserve in vivo evaluation in order to verify their potential in the treatment of infections caused by M. pachydermatis.Malassezia pachydermatis é uma levedura pertencente à microbiota normal de animais e, usualmente, apontada como responsável por otites externas e recentemente por diversas formas de dermatites, principalmente em cães. Este estudo teve como objetivo avaliar a suscetibilidade in vitro de 26 isolados de M. pachydermatis frente aos antifúngicos fluconazol, itraconazol, cetoconazol, clotrimazol, miconazol, terbinafina e nistatina, e combinações desses com timol, carvacrol e cinamaldeído, através do método de checkerboard , baseado no documento M27-A3. Também foram avaliadas a atividade do itraconazol, cetoconazol e clotrimazol, em 20 isolados de M. pachydermatis, através da exposição simultânea e sequencial desses agentes utilizando-se a técnica de disco-difusão. Isoladamente, as concentrações inibitórias mínimas (CIMs) para o fluconazol variaram de 1- 64 μg/mL, para o itraconazol 0,01-1 μg/mL, para o cetoconazol 0,01-0,5 μg/mL, para o clotrimazol 0,5-32 μg/mL, para o miconazol 2-32 μg/mL, para a terbinafina 0,12-32 μg/mL e para a nistatina 16-64 μg/mL. Altas taxas de sinergismo foram observadas nas combinações de nistatina + timol (88,46%), nistatina + carvacrol (88,46%), nistatina + cinamaldeído (73,07%), clotrimazol + timol (69,23%), clotrimazol + carvacrol (69,23%), miconazol + timol (65,38%), miconazol + carvacrol (76,92%) e miconazol + cinamaldeído (65,38%). No entanto, fluconazol + timol (53,84%), fluconazol + carvacrol (46,15%), fluconazol + cinamaldeído (65,38%), itraconazol + timol (61,53%), itraconazol + carvacrol (69,23%), itraconazol + cinamaldeído (65,38%), terbinafina + timol (73,07%), terbinafina + carvacrol (65,38%), terbinafina + cinamaldeído (73,07%) e clotrimazol + cinamaldeído (61,53%) tiveram altas taxas de indiferença. Cetoconazol combinado com timol, carvacrol e cinamaldeído apresentaram as maiores taxas de antagonismo (42,3%). A exposição prévia de M. pachydermatis ao itraconazol resultou em uma diminuição da zona de inibição, quando comparado com o itraconazol e cetoconazol usados simultaneamente (p <0,01). Por outro lado, a exposição prévia do clotrimazol aumentou significativamente a zona de inibição (p <0,001), quando comparado à exposição simultânea de clotrimazol e itraconazol. As associações de maior relevância merecem avaliação in vivo, a fim de verificar o potencial das mesmas no tratamento de infecções por M. pachydermatis.Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorapplication/pdfporUniversidade Federal de Santa MariaPrograma de Pós-Graduação em FarmacologiaUFSMBRFarmacologiaMalassezia pachydermatisSuscetibilidadeIn vitroMalassezia pachydermatisSusceptibilityIn vitroCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIASuscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciaisIn vitro susceptibility of Malassezia pachydermatis against antifungal agents and essential oil fractionsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisSanturio, Janio Moraishttp://lattes.cnpq.br/6316012260769979Alves, Sydney Hartzhttp://lattes.cnpq.br/0330782478769631Loreto, Érico Silva dehttp://lattes.cnpq.br/5475233864057995http://lattes.cnpq.br/2330632247520007Schlemmer, Karine Bizzi20100000000040050030050050006a1b29c-fde0-4a69-8097-2a9d6a9d964986be3930-0495-4583-b4ce-11d61591fd607928080e-16be-47fd-b0a3-6d394fcd82a7ea251119-5531-432f-bf54-8c8111248727info:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSMORIGINALSCHLEMMER, KARINE BIZZI.pdfapplication/pdf1885689http://repositorio.ufsm.br/bitstream/1/9007/1/SCHLEMMER%2c%20KARINE%20BIZZI.pdff4e062790d7d72884d2766e50f42aaf1MD51TEXTSCHLEMMER, KARINE BIZZI.pdf.txtSCHLEMMER, KARINE BIZZI.pdf.txtExtracted texttext/plain194408http://repositorio.ufsm.br/bitstream/1/9007/2/SCHLEMMER%2c%20KARINE%20BIZZI.pdf.txt455c8b9d20903f7e10d52ee88105a8cbMD52THUMBNAILSCHLEMMER, KARINE BIZZI.pdf.jpgSCHLEMMER, KARINE BIZZI.pdf.jpgIM Thumbnailimage/jpeg4726http://repositorio.ufsm.br/bitstream/1/9007/3/SCHLEMMER%2c%20KARINE%20BIZZI.pdf.jpg9d056acb862195fc48cf4bb6b9cdf85eMD531/90072022-01-28 10:36:43.3oai:repositorio.ufsm.br:1/9007Repositório Institucionalhttp://repositorio.ufsm.br/PUBhttp://repositorio.ufsm.br/oai/requestopendoar:39132022-01-28T13:36:43Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false |
dc.title.por.fl_str_mv |
Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais |
dc.title.alternative.eng.fl_str_mv |
In vitro susceptibility of Malassezia pachydermatis against antifungal agents and essential oil fractions |
title |
Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais |
spellingShingle |
Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais Schlemmer, Karine Bizzi Malassezia pachydermatis Suscetibilidade In vitro Malassezia pachydermatis Susceptibility In vitro CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
title_short |
Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais |
title_full |
Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais |
title_fullStr |
Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais |
title_full_unstemmed |
Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais |
title_sort |
Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais |
author |
Schlemmer, Karine Bizzi |
author_facet |
Schlemmer, Karine Bizzi |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Santurio, Janio Morais |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/6316012260769979 |
dc.contributor.referee1.fl_str_mv |
Alves, Sydney Hartz |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/0330782478769631 |
dc.contributor.referee2.fl_str_mv |
Loreto, Érico Silva de |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/5475233864057995 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/2330632247520007 |
dc.contributor.author.fl_str_mv |
Schlemmer, Karine Bizzi |
contributor_str_mv |
Santurio, Janio Morais Alves, Sydney Hartz Loreto, Érico Silva de |
dc.subject.por.fl_str_mv |
Malassezia pachydermatis Suscetibilidade In vitro |
topic |
Malassezia pachydermatis Suscetibilidade In vitro Malassezia pachydermatis Susceptibility In vitro CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
dc.subject.eng.fl_str_mv |
Malassezia pachydermatis Susceptibility In vitro |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
description |
The yeast Malassezia pachydermatis belongs to the normal microbiota of animals, and is usually implicated as responsible for otitis media and recently by various forms of dermatitis, mainly in dogs. This study aimed to evaluate the in vitro susceptibility of 26 M. pachydermatis isolates against the antifungals fluconazole, itraconazole, ketoconazole, clotrimazole, miconazole, terbinafine and nystatin, and to the combinations of these with thymol, carvacrol and cinnamaldehyde by the checkerboard method, based on document M27-A3. The activity of itraconazol, ketoconazole and clotrimazole against 20 isolates of M. pachydermatis, through simultaneous and sequential exposure of these agents, was also evaluated by the disk-diffusion technique. The minimum inhibitory concentration (MIC) for fluconazole ranged from 1-64 μg/mL, itraconazole 0.01-1 μg/mL, ketoconazole 0.01-0.5 μg/mL, clotrimazole 0.5-32 μg/mL, miconazole 2-32 μg/mL, terbinafine 0.12-32 μg/mL and nystatin 16-64 μg/mL. High rates of synergism were observed in the combinations of nystatin + thymol (88.46%), nystatin + carvacrol (88.46%), nystatin + cinnamaldehyde (73.07%), clotrimazole + thymol (69.23%), clotrimazole + carvacrol (69.23%), miconazole + thymol (65.38%), miconazole + carvacrol (76.92%) and miconazole + cinnamaldehyde (65.38%). However, high rates of indifference were observed in the combinations of fluconazole + thymol (53.84%), carvacrol + fluconazole (46.15%), fluconazole + cinnamaldehyde (65.38%), thymol + itraconazole (61.53%), carvacrol + itraconazole (69.23%), itraconazole + cinnamaldehyde (65.38%), terbinafine + thymol (73.07%), terbinafine + carvacrol (65.38%), terbinafine + cinnamaldehyde (73.07%) and clotrimazole + cinnamaldehyde (61.53%). Ketoconazole combined with thymol, carvacrol and cinnamaldehyde had the highest rates of antagonism (42.3%). The prior exposure of M. pachydermatis to itraconazole resulted in a reduction of the inhibition halo when compared with itraconazole and ketoconazole used simultaneously (p <0.01). Moreover, prior exposure of clotrimazole significantly increased the zone of inhibition (p <0.001) when compared to the simultaneous exposure of itraconazole and clotrimazole. The most significant associations deserve in vivo evaluation in order to verify their potential in the treatment of infections caused by M. pachydermatis. |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014-03-14 |
dc.date.accessioned.fl_str_mv |
2015-03-12 |
dc.date.available.fl_str_mv |
2015-03-12 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
SCHLEMMER, Karine Bizzi. IN VITRO SUSCEPTIBILITY OF Malassezia pachydermatis AGAINST ANTIFUNGAL AGENTS AND ESSENTIAL OIL FRACTIONS. 2014. 139 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014. |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufsm.br/handle/1/9007 |
identifier_str_mv |
SCHLEMMER, Karine Bizzi. IN VITRO SUSCEPTIBILITY OF Malassezia pachydermatis AGAINST ANTIFUNGAL AGENTS AND ESSENTIAL OIL FRACTIONS. 2014. 139 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014. |
url |
http://repositorio.ufsm.br/handle/1/9007 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.cnpq.fl_str_mv |
201000000000 |
dc.relation.confidence.fl_str_mv |
400 500 300 500 500 |
dc.relation.authority.fl_str_mv |
06a1b29c-fde0-4a69-8097-2a9d6a9d9649 86be3930-0495-4583-b4ce-11d61591fd60 7928080e-16be-47fd-b0a3-6d394fcd82a7 ea251119-5531-432f-bf54-8c8111248727 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Santa Maria |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Farmacologia |
dc.publisher.initials.fl_str_mv |
UFSM |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Farmacologia |
publisher.none.fl_str_mv |
Universidade Federal de Santa Maria |
dc.source.none.fl_str_mv |
reponame:Manancial - Repositório Digital da UFSM instname:Universidade Federal de Santa Maria (UFSM) instacron:UFSM |
instname_str |
Universidade Federal de Santa Maria (UFSM) |
instacron_str |
UFSM |
institution |
UFSM |
reponame_str |
Manancial - Repositório Digital da UFSM |
collection |
Manancial - Repositório Digital da UFSM |
bitstream.url.fl_str_mv |
http://repositorio.ufsm.br/bitstream/1/9007/1/SCHLEMMER%2c%20KARINE%20BIZZI.pdf http://repositorio.ufsm.br/bitstream/1/9007/2/SCHLEMMER%2c%20KARINE%20BIZZI.pdf.txt http://repositorio.ufsm.br/bitstream/1/9007/3/SCHLEMMER%2c%20KARINE%20BIZZI.pdf.jpg |
bitstream.checksum.fl_str_mv |
f4e062790d7d72884d2766e50f42aaf1 455c8b9d20903f7e10d52ee88105a8cb 9d056acb862195fc48cf4bb6b9cdf85e |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM) |
repository.mail.fl_str_mv |
|
_version_ |
1801223745321304064 |